Sugi Predict

Sugi Predict / Compounds / SCHEMBL4950195

SCHEMBL4950195

SCHEMBL4950195

Cc1ccc(O)cc1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.47
▸ SIRT3 Q9NTG7 1/20 0.47
▸ LCK P06239 1/20 0.46
▸ CA12 O43570 3/20 0.43
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA7 P43166 3/20 0.43
▸ CA9 Q16790 3/20 0.43
▸ CA14 Q9ULX7 3/20 0.43
▸ ALOX5 P09917 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ PARP1 P09874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5952602 0.83 MKNK1 (0.47) TDP1SIRT3LCKCA12CA1
SCHEMBL30344092 0.80 CA12 (0.61) TDP1LCKCA12CA1CA2
SCHEMBL1334366 0.80 CA12 (0.61) TDP1LCKCA12CA1CA2
SCHEMBL9216747 0.80 HSD17B1 (0.47) TDP1CA12CA1CA2CA7
SCHEMBL1003845 0.80 MEN1 (0.53) TDP1SIRT3MAPTMEN1KMT2A
SCHEMBL1805264 0.79 CES2 (0.50) LCKCA12CA1CA2CA7
Hydrochloric Acid SCHEMBL28266821 0.78 MEN1 (0.52) TDP1SIRT3MAPTMEN1KMT2A
SCHEMBL328278 0.78 CASP1 (0.50) TDP1SIRT3PTGS2MAPTMEN1
SCHEMBL6825758 0.78 PARP1 (0.50) TDP1SIRT3LCKCA1CA2
SCHEMBL18861032 0.78 CA12 (0.43) TDP1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709716-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
EP-4371987-B9 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-11-26 — — EP disclosed
EP-4371987-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-09-17 — — EP disclosed
US-12258346-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2025-03-25 — — US disclosed
WO-2024233554-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2024-11-14 — — WO disclosed
US-20240287061-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2024-08-29 — — US disclosed
CN-113227089-B Substituted 6-azabenzimidazole compounds as HPK1 inhibitors 吉利德科学公司 2024-07-05 — — CN disclosed
EP-4371987-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS Gilead Sciences, Inc. (US) 2024-05-22 — — EP disclosed
US-11897878-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2024-02-13 — — US disclosed
EP-3873903-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2024-01-24 — — EP disclosed
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2021-04-22 — — US disclosed
US-7365085-B2 Compounds and methods SMITHKLINE BEECHAM CORPORATION (US) 2008-04-29 — — US disclosed
WO-2006047528-A2 PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-04 — — WO disclosed
EP-1575495-A2 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2005-09-21 — — EP disclosed
US-20050113580-A1 Amide compounds and methods of using the same SMITHKLINE BEECHAM CORP 2005-05-26 — — US disclosed
WO-2005032468-A2 MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 — — WO disclosed
WO-2004041776-A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-21 — — WO disclosed
WO-2004037176-A2 QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-06 — — WO disclosed
WO-2004031145-A2 LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-15 — — WO disclosed
WO-2003082205-A2 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287061-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK TDP1 1031/4885SIRT3 1555/4885LCK 488/4885
US-12258346-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK TDP1 1031/4885SIRT3 1555/4885LCK 488/4885
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK TDP1 1031/4885SIRT3 1555/4885LCK 488/4885
US-20050113580-A1 Amide compounds and methods of using the same NR1H2, NR1H3, PPARA TDP1 4665/4885SIRT3 227/4885LCK 2120/4885
US-11897878-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK TDP1 1031/4885SIRT3 1555/4885LCK 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.